CN103599320A - 一种治疗系统性硬化病的中药颗粒剂及其制备方法 - Google Patents
一种治疗系统性硬化病的中药颗粒剂及其制备方法 Download PDFInfo
- Publication number
- CN103599320A CN103599320A CN201310351880.2A CN201310351880A CN103599320A CN 103599320 A CN103599320 A CN 103599320A CN 201310351880 A CN201310351880 A CN 201310351880A CN 103599320 A CN103599320 A CN 103599320A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- preparation
- systemic sclerosis
- extraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 48
- 206010042953 Systemic sclerosis Diseases 0.000 title claims abstract description 34
- 239000008187 granular material Substances 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 201000009594 Systemic Scleroderma Diseases 0.000 title claims abstract description 24
- 241000756943 Codonopsis Species 0.000 claims abstract description 13
- 239000009636 Huang Qi Substances 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 235000006463 Brassica alba Nutrition 0.000 claims abstract description 5
- 244000140786 Brassica hirta Species 0.000 claims abstract description 5
- 238000000605 extraction Methods 0.000 claims description 24
- 238000002054 transplantation Methods 0.000 claims description 14
- 239000000341 volatile oil Substances 0.000 claims description 14
- 241000345998 Calamus manan Species 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 12
- 235000013399 edible fruits Nutrition 0.000 claims description 12
- 235000012950 rattan cane Nutrition 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 239000002674 ointment Substances 0.000 claims description 9
- 239000012153 distilled water Substances 0.000 claims description 6
- 239000003651 drinking water Substances 0.000 claims description 6
- 235000020188 drinking water Nutrition 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 241000167550 Centella Species 0.000 claims description 4
- 235000005903 Dioscorea Nutrition 0.000 claims description 4
- 241000234273 Dioscorea Species 0.000 claims description 4
- 235000000504 Dioscorea villosa Nutrition 0.000 claims description 4
- 241000545442 Radix Species 0.000 claims description 4
- 235000004879 dioscorea Nutrition 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 102000011759 adducin Human genes 0.000 claims description 3
- 108010076723 adducin Proteins 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- 230000002829 reductive effect Effects 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 239000002893 slag Substances 0.000 claims description 3
- 230000003068 static effect Effects 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 238000003809 water extraction Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 16
- 230000006870 function Effects 0.000 abstract description 8
- 230000004199 lung function Effects 0.000 abstract description 3
- 238000010792 warming Methods 0.000 abstract description 3
- 244000302544 Luffa aegyptiaca Species 0.000 abstract 2
- 235000009814 Luffa aegyptiaca Nutrition 0.000 abstract 2
- 244000140995 Capparis spinosa Species 0.000 abstract 1
- 235000017336 Capparis spinosa Nutrition 0.000 abstract 1
- 244000146462 Centella asiatica Species 0.000 abstract 1
- 235000004032 Centella asiatica Nutrition 0.000 abstract 1
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 1
- 235000002722 Dioscorea batatas Nutrition 0.000 abstract 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 abstract 1
- 240000001811 Dioscorea oppositifolia Species 0.000 abstract 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 abstract 1
- 241000893536 Epimedium Species 0.000 abstract 1
- 235000018905 epimedium Nutrition 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 24
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000008280 blood Substances 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 230000010354 integration Effects 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 6
- 210000001835 viscera Anatomy 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 206010016654 Fibrosis Diseases 0.000 description 4
- 208000003782 Raynaud disease Diseases 0.000 description 4
- 208000012322 Raynaud phenomenon Diseases 0.000 description 4
- 230000003064 anti-oxidating effect Effects 0.000 description 4
- 230000004761 fibrosis Effects 0.000 description 4
- 229930003935 flavonoid Natural products 0.000 description 4
- 150000002215 flavonoids Chemical class 0.000 description 4
- 235000017173 flavonoids Nutrition 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 206010034133 Pathogen resistance Diseases 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 229960001639 penicillamine Drugs 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 208000032081 Cabezas type X-linked intellectual disability Diseases 0.000 description 1
- WCNPJVPXLWJQIR-HKSFMPNISA-N Codonopsine Chemical compound C1=C(OC)C(OC)=CC=C1[C@H]1N(C)[C@H](C)[C@@H](O)[C@@H]1O WCNPJVPXLWJQIR-HKSFMPNISA-N 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001826 anti-prostatic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- WCNPJVPXLWJQIR-UHFFFAOYSA-N codonopsine Natural products C1=C(OC)C(OC)=CC=C1C1N(C)C(C)C(O)C1O WCNPJVPXLWJQIR-UHFFFAOYSA-N 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000004383 glucosinolate group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- -1 lignanoid Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001197 polyacetylene Polymers 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000014860 sensory perception of taste Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 201000001872 syndromic X-linked intellectual disability Cabezas type Diseases 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 229930183580 tangshenoside Natural products 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 229930182493 triterpene saponin Natural products 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310351880.2A CN103599320B (zh) | 2013-08-14 | 2013-08-14 | 一种治疗系统性硬化病的中药颗粒剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310351880.2A CN103599320B (zh) | 2013-08-14 | 2013-08-14 | 一种治疗系统性硬化病的中药颗粒剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103599320A true CN103599320A (zh) | 2014-02-26 |
CN103599320B CN103599320B (zh) | 2015-09-09 |
Family
ID=50117626
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310351880.2A Expired - Fee Related CN103599320B (zh) | 2013-08-14 | 2013-08-14 | 一种治疗系统性硬化病的中药颗粒剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103599320B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104840672A (zh) * | 2015-04-13 | 2015-08-19 | 南阳理工学院 | 温阳化浊通络方免疫抑制作用有效部位的提取筛选方法 |
CN105497704A (zh) * | 2015-12-23 | 2016-04-20 | 关东升 | 一种治疗多发性硬化病的中药 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102000202A (zh) * | 2010-11-30 | 2011-04-06 | 李华 | 一种治疗硬皮病的中药 |
-
2013
- 2013-08-14 CN CN201310351880.2A patent/CN103599320B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102000202A (zh) * | 2010-11-30 | 2011-04-06 | 李华 | 一种治疗硬皮病的中药 |
Non-Patent Citations (3)
Title |
---|
李凡等: "维吾尔药槌果藤治疗硬皮病6例", 《中华皮肤科杂志》, vol. 30, no. 1, 28 February 1997 (1997-02-28), pages 53 - 54 * |
秦万章: "硬皮病的中医疗法", 《中医杂志》, no. 8, 31 December 1986 (1986-12-31), pages 62 - 64 * |
郭刚等: "中医药治疗系统性硬化症现状及评述", 《风湿病与关节炎》, vol. 1, no. 3, 31 December 2012 (2012-12-31), pages 64 - 69 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104840672A (zh) * | 2015-04-13 | 2015-08-19 | 南阳理工学院 | 温阳化浊通络方免疫抑制作用有效部位的提取筛选方法 |
CN105497704A (zh) * | 2015-12-23 | 2016-04-20 | 关东升 | 一种治疗多发性硬化病的中药 |
Also Published As
Publication number | Publication date |
---|---|
CN103599320B (zh) | 2015-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103830535B (zh) | 治疗鼻炎的药物组合物及其制备方法和用途 | |
CN104127531A (zh) | 一种治疗肠胃炎的中药组合物及其制备方法 | |
CN102600423A (zh) | 用于治疗肝纤维化的中药制备方法 | |
CN103830632A (zh) | 一种根治银屑病等多种皮肤病的中药制剂及其制备方法与应用 | |
CN107158223A (zh) | 用于清热解毒与消炎的中药制剂及其制备方法 | |
CN103182064A (zh) | 一种治疗风寒咳嗽的药物及其制备方法 | |
CN103599320B (zh) | 一种治疗系统性硬化病的中药颗粒剂及其制备方法 | |
CN111298021A (zh) | 一种治疗功能性便秘的中药组合物 | |
CN103041151A (zh) | 治疗气管炎的中药组合物及其制备方法 | |
CN103446445B (zh) | 治疗气阴两虚型慢性支气管炎的中药制剂及其制备方法 | |
CN104645232A (zh) | 一种治疗双曲综合征的中药复合组合物及其制备方法和应用 | |
CN103006985A (zh) | 一种治疗失眠症的中药验方 | |
CN102552767B (zh) | 治疗肾结石的中药、制备方法及给药方式 | |
CN104887950A (zh) | 一种治疗乳痈的中药组合物 | |
CN104771513A (zh) | 治疗胆囊炎的中药组合物 | |
CN103877484A (zh) | 一种治疗慢性肠炎的中药口服液 | |
CN104435079A (zh) | 一种治疗痛风的中药组合物 | |
CN103961562A (zh) | 一种治疗阴虚火旺型复发性口疮的浓缩型口服液 | |
CN103432335B (zh) | 一种治疗乳糜尿的药物及其制备方法 | |
CN105079689A (zh) | 一种治疗非化脓性脂膜炎的内服药物及其制备方法 | |
CN105770815A (zh) | 一种含有艾叶的治疗产后虚脱的中药组合物及其制备方法 | |
CN106806814A (zh) | 用于治疗非酒精性脂肪肝的中药组合物及其制备方法 | |
CN104707124A (zh) | 一种治疗慢性子宫内膜炎的中药制剂 | |
CN104623387A (zh) | 一种用于治疗慢性肾炎的药物组合物 | |
CN103566226B (zh) | 一种治疗化脓性肺炎的中药 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: BIAN HUA Effective date: 20150630 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Bian Hua Inventor after: Lv Qin Inventor after: Li Yan Inventor after: Zhang Weiping Inventor after: Song Yunmei Inventor after: Zhang Chaoyun Inventor after: Fu Weiyun Inventor after: Mao Bingyu Inventor before: Bian Hua Inventor before: Lv Qin Inventor before: Han Huagang Inventor before: Zhang Weiping Inventor before: Song Yunmei Inventor before: Zhang Chaoyun Inventor before: Fu Weiyun Inventor before: Mao Bingyu |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: BIAN HUA LV QIN HAN HUAGANG ZHANG WEIPING SONG YUNMEI ZHANG CHAOYUN FU WEIYUN MAO BINGYU TO: BIAN HUA LV QIN LI YAN ZHANG WEIPING SONG YUNMEI ZHANG CHAOYUN FU WEIYUN MAO BINGYU |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20150630 Address after: 473000 Changjiang Road, Henan, Nanyang, No. 80 Applicant after: Nanyang Science Technology College Address before: 473004 Zhang Zhongjing Medical College, Nanyang Institute of Technology, 80 Changjiang Road, Henan, Nanyang Applicant before: Nanyang Science Technology College Applicant before: Bian Hua |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150909 Termination date: 20180814 |